These novel findings shed light on the understanding of PD-L1-mediated immune tolerance and suggest the potential therapeutic targeting of Klf1 and Egr2 in the treatment of autoimmune diseases and malignancies. This evidence concerns the gene EGR2 and autoimmune disease.